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CA IX is a hypoxia-induced, cancer-associated carbonic anhydrase isoform with functional involvement in pH control and cell
adhesion. Here we describe an alternative splicing variant of the CA9 mRNA, which does not contain exons 8–9 and is expressed in
tumour cells independently of hypoxia. It is also detectable in normal tissues in the absence of the full-length transcript and can
therefore produce false-positive data in prognostic studies based on the detection of the hypoxia- and cancer-related CA9
expression. The splicing variant encodes a truncated CA IX protein lacking the C-terminal part of the catalytic domain. It shows
diminished catalytic activity and is intracellular or secreted. When overexpressed, it reduces the capacity of the full-length CA IX
protein to acidify extracellular pH of hypoxic cells and to bind carbonic anhydrase inhibitor. HeLa cells transfected with the splicing
variant cDNA generate spheroids that do not form compact cores, suggesting that they fail to adapt to hypoxic stress. Our data
indicate that the splicing variant can functionally interfere with the full-length CA IX. This might be relevant particularly under
conditions of mild hypoxia, when the cells do not suffer from severe acidosis and do not need excessive pH control.
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Carbonic anhydrase IX (CA IX) is one of 12 enzymatically active
carbonic anhydrase isoforms expressed in the human body. These
zinc metalloenzymes catalyse a reversible conversion of carbon
dioxide to bicarbonate and proton, and thereby contribute to
modulation of ion transport and maintenance of acid-base balance.
The CA isoforms show remarkable diversity in their enzyme
activity, kinetic properties, distribution in tissues, localisation in
subcellular compartments and sensitivity to inhibitors. This
diversity enables them to fulfill specific roles in metabolically
active organs and in various physiological situations (Pastorekova
et al, 2004).
In contrast to the majority of CA isoforms that are mostly
present in differentiated cells of the normal tissues, CA IX
expression is predominantly associated with a broad range of
tumours derived from cells, which contain no or low level of CA IX
(Potter and Harris, 2003). The only normal tissues that show
moderate-to-abundant expression of CA IX belong to gastro-
intestinal tract and comprise epithelia of the glandular stomach,
small intestine, and gallbladder (Pastorekova et al, 1997).
The tumour-related expression pattern of CA IX is principally
determined by a strong activation of CA9 gene transcription via a
hypoxia-inducible factor (HIF), which binds to hypoxia responsive
element (HRE) localised in the minimal CA9 promoter proximal to
transcription start site at  10/ 3 position (Wykoff et al, 2000).
The HIF transcription factor significantly changes the expression
profile of weakly oxygenated tumour cells by the activation of
genes that either support their survival and adaptation to hypoxic
stress or lead to their death. As a result, hypoxia selects more
aggressive tumour cells with increased capability to invade and
metastasise and is therefore inherently associated with bad
prognosis and poor response to anticancer therapy (Harris, 2002).
Strong induction by HIF, hypoxia-related intratumoral distribu-
tion, and the relationship to cancer development and/or treatment
outcome predispose CA IX to serve as a surrogate marker of
hypoxia with a prognostic value (Potter and Harris, 2003).
Moreover, CA IX also appears to play an active role in tumour
biology via modulation of cell adhesion and control of pH
(Svastova et al, 2003; Svastova et al, 2004; Swietach et al, 2007). CA
IX participates in bicarbonate transport metabolon and contri-
butes to acidification of extracellular microenvironment in
response to hypoxia (Svastova et al, 2004; Morgan et al, 2007).
Here we show that the CA9 gene expression involves alternative
splicing and describe the alternatively spliced (AS) variant of CA9
mRNA. We demonstrate that the AS variant is less abundant than
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According to the carbonic anhydrase nomenclature, human CA
isoenzymes are written in capital Roman letters and numbers, while
their genes are written in Italic letters and Arabic numbers. The genes
encoding rodent carbonic anhydrases are designated Car, but their
products are abbreviated CA such as the other mammalian CAs.
British Journal of Cancer (2008) 98, 129–136
& 2008 Cancer Research UK All rights reserved 0007– 0920/08 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sthe full-length (FL) CA9 mRNA in tumours, but in contrast, can be
detected in normal tissues and under normoxia. The human AS
mRNA does not contain exons 8–9 and codes for a truncated CA
IX protein. The AS CA IX is not confined to the plasma membrane,
shows reduced catalytic activity upon overexpression in HeLa cells,
reduces hypoxia-induced extracellular acidification, and compro-
mises growth of HeLa spheroids. Because the AS variant can be
present in the normoxic cells with normal phenotype in the
absence of FL CA IX, it can produce false-positive results in the
studies designed to assess hypoxia- and tumour-related expression
of CA9 gene with prognostic intent. Moreover, it may functionally
interfere with the FL CA IX, especially under moderate hypoxia,
when the FL levels are relatively low.
MATERIALS AND METHODS
Cell culture, tissues, and antibodies
Canine MDCK epithelial cells, human tumour cell lines CAKI-1,
and ACHN derived from kidney carcinoma, as well as Caski,
SiHa, HeLa, and C33a lines from cervical carcinoma were
cultivated in DMEM supplemented with 10% fetal calf serum
(FCS) (BioWhittaker, Verviers, Belgium) and 40mgml
 1 gentami-
cin (Lek, Ljubljana, Slovenia) in a humidified atmosphere with 5%
CO2 at 371C. Hypoxic treatments were performed in an anaerobic
workstation (Ruskin Technologies, Bridgend, UK) in 2% O2,5 %
CO2, 10% H2, and 83% N2 at 371C. To achieve different cell density,
7 10
5 cells were plated to dishes of different diameters (3.5cm,
6cm, and 10cm), allowed to adhere for 24h and grow for
additional 24h in normoxia or parallel in hypoxia.
HeLa spheroids were preformed from 400 cells per 20mlo f
culture medium in drops hanging on the lid of a tissue culture
dish for three days at 371C. The resulting cell aggregates were
transferred to a Petri dish with a non-adherent surface and
cultivated in suspension for an additional 11 days, with medium
exchange every third day. The spheroids were examined with a
Nikon E400 microscope and photographed with a Nikon Coolpix
990 camera.
Human tissues were selected from the collection described
previously (Kivela et al, 2005). M75 and V/10 mouse MAbs specific
for the human MN/CA IX protein were characterised earlier
(Pastorekova et al, 1992; Zatovicova et al, 2003). Rat monoclonal
anti-a-tubulin antibody (clone YL 1/2) in an undiluted hybridoma
medium (described by Kilmartin et al 1982, and kindly provided
by Professor M Novak, Institute of Neuroimmunology, Slovak
Academy of Sciences, Bratislava) was used as a loading control.
Secondary anti-mouse and anti-rat peroxidase-conjugated anti-
bodies were from Sevapharma (Prague, Czech Republic). Anti-
mouse FITC-conjugated antibodies were from Vector Laboratories
(Burlingame, CA, USA). Immunofluorescence was performed as
before (Svastova et al, 2004). Antibodies against the mouse CA IX
protein were described elsewhere (Gut et al, 2002).
Expression plasmids
The eukaryotic expression plasmid pSG5C-AS encoding the human
splicing variant was generated by inverse PCR from the pSG5C-
MN/CA9 expression plasmid (Pastorek et al, 1994) that contains
a full-length human CA9 cDNA (GenBank no. X66839) using
the primers to exons 10 and 7. The forward primer (h10S,
50-GTGACATCCTAGCCCTGGTTTTT-30) was specific to the start
of exon 10 and the reverse primer (h7A, 50-CTGCTTAGCACTCAG
CATCACTG-30) was specific to the end of exon 7. The same h7A
and h10S primers were used for the preparation of a bacterial
expression vector pGEX-3X-AS encoding a GST-fused splice
variant of the human CA IX protein, from the primary plasmid
construct pGEX-3X-CA9 coding for the full-length CA IX protein
without the signal peptide. PCR amplifications were performed
using a Phusion polymerase (Finnzymes, Espoo, Finland). Poly-
merase chain reactions consisting of an initial denaturing at 981C
for 30s, 32 cycles of denaturing at 981C for 10s, annealing at 641C
for 30s, extension at 721C for 1min 40s, and final extension for
5min at 721C. Polymerase chain reaction products were gel-
purified, treated with T4 polynucleotide kinase and ligated with T4
DNA ligase (Invitrogen, Carlsbad, CA, USA). All constructs were
verified by sequencing. The construct coding for GST-PGCA fusion
protein containing the extracellular part of the human CA IX was
described earlier (Zatovicova et al, 2003).
Transfection
The cells were plated in 60mm Petri dishes to reach approximately
70% density on the next day. Transfection was performed with 2mg
of the pSG5C-AS plasmid together with 200ng of pSV2neo plasmid
using the Gene Porter II transfection reagent (Genlantis, San Diego,
CA, USA). The transfected cells were subjected to selection using
G418 (Invitrogen, Carlsbad, CA, USA) at a concentration of
900mgml
 1 for HeLa cells, and 500mgml
 1 for MDCK cells. The
resistant colonies were cloned, tested for expression of the splicing
variant by immunoblotting and expanded.
Binding of fluorescent CA inhibitor
The fluorescent CA inhibitor (FITC-CAI) was obtained by reaction
of homosulphanilamide with fluorescein isothiocyanate and
showed a KI value of 24nM towards CA IX (Svastova et al, 2004;
Cecchi et al, 2005). The inhibitor was dissolved in PBS with 20%
DMSO at 100mM concentration and diluted in a culture medium
to a final 1mM concentration just before addition to cells. The
MDCK-CA IX cells (Svastova et al, 2004) were plated at a density
of 400000 cells per 3.5cm dish in the medium containing the
conditioned medium from MDCK-AS transfectants that secrete the
human AS variant. Control cells were incubated in the absence
of secreted AS. After 24h incubation, equivalent fresh media
were replenished, FITC-CAI was added to cells, the cells were
transferred to the hypoxic workstation, and binding was allowed
for additional 48h. Parallel samples were incubated in normoxia.
At the end, the cells were washed five times with PBS and viewed
by a Nikon E400 epifluorescence microscope. Intensity of the
fluorescence was evaluated from acquired images using the Scion
Image b 4.02 software (Scion Corporation, Frederick, MD, USA)
and relative FITC-CAI binding was expressed in per cent.
Immunoprecipitation and immunoblotting
Proteins were extracted from the cell monolayer or tissue
homogenate with RIPA buffer as described previously (Svastova
et al, 2004). The samples for the detection of extracellular human
AS were prepared from the culture medium of AS-transfected cells
incubated without FCS under hypoxia and normoxia for 24h. One-
fourth (500ml) of the culture medium was 10 times concentrated
and separated in SDS–PAGE. For immunoprecipitation, CA IX-
specific MAbs in 1ml of hybridoma medium were bound to 25ml
50% suspension of Protein-A Sepharose (Pharmacia, Uppsala,
Sweden) for 2h at RT. Cell extract (200ml) was pre-cleared
with 20ml of 50% suspension of Protein-A Sepharose and then
added to the bound MAbs. Immunocomplexes collected on
Protein-A Sepharose were washed, boiled, and subjected to
SDS–PAGE on 10% gel and to immunoblotting as described
previously (Zatovicova et al, 2003).
For the isolation of membrane and sub-membrane proteins
and analysis of oligomers, the cells were washed with PBS and
incubated with RIPA extraction buffer for 30s on ice. RIPA buffer
with proteins was aspirated and fresh RIPA buffer was added to the
cells. The remaining proteins were then extracted for 15min on
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sice. Oligomers were first immunoprecipitated from HeLa-AS
extract using the CA IX-specific MAbs V/10 (recognises FL but
not AS) or M75 (recognises both variants). Components of the
precipitated oligomers were resolved in reducing SDS–PAGE,
blotted and visualised using the peroxidase-labelled M75.
Reverse transcription PCR
Total RNA was isolated either from cells or from tissues using
InstaPure reagent (Eurogentec, Seraing, Belgium). Reverse tran-
scription was performed with M-MuLV reverse transcriptase
(Finnzymes, Oy, Finland) using random heptameric primers
(400ngml
 1). The mixture of 5mg of total RNA and random
primers (400ngml
 1) was heated for 10min at 701C, cooled quickly
on ice and supplemented with 0.5mM dNTPs (Finnzymes), reverse
transcriptase buffer containing 6mM MgCl2,4 0 m M KCl, 1mM
DTT, 0.1mgml
 1 BSA, and 50mM Tris–HCl, pH 8.3. The mixture
in a final volume of 24ml was further supplemented with 200U of
reverse transcriptase M-MuLV, incubated for 1h at 421C, heated
for 15min at 701C, and stored at  801C until used.
PCR was performed with Dynazyme EXT polymerase
(Finnzymes) with the primers listed in Supplementary Table 1.
The protocol of PCR consisted of 941C for 3min followed by
30 cycles of denaturing at 941C for 30s, annealing for 40s
(temperature depended on sets of primers), and extension at 721C
for 40s, followed by a final extension at 721C for 5min. Resulting
PCR fragments were run on 1.5% agarose gels along with the
SmartLadder (Eurogentech, Seraing, Belgium). The intensity of
bands corresponding to individual PCR products was evaluated
with ImageJ 1.34s software (Rasband, WS, ImageJ, US National
Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/,
1997–2007). ImageJ can create density histograms and calculate
area and pixel value statistics of user-defined selections. The
amount of PCR products was semiquantitatively expressed as
the ratio of the intensity of each band to the intensity of the related
b-actin internal standard.
The PCR products were purified and sequenced using an
automatic sequencer from Applied Biosystems ABI 3100 (Foster
City, CA, USA) to verify their identity.
Real-time PCR
Total RNA isolated from the human stomach, small intestine, and
colon was obtained from BD Biosciences, San Jose, CA, USA. In
addition, RNA isolated by Instapure from normoxic and hypoxic
SiHa, Caski and ACH carcinoma cells was used. Reverse
transcription was performed with M-MuLV reverse transcriptase
as described above. Real-time PCR was performed with DyNAmo
t
HS SYBR
s Green qPCR kit (Finnzymes) with primers specific for
FL (h8A) and AS (h10/7A), respectively, combined with h7S primer
common for both transcripts. Real-time PCR was run on TECHNE
QUANTICA (Duxford, Cambridge, UK), using the following
programme, UNG incubation at 501C for 5min, initial denatura-
tion at 951C for 15min followed by cycling (45 cycles) denatura-
tion at 951C for 10s, annealing at 641C for 20s, extension at 721C
for 30s, and final extension for 7min at 721C. All PCRs were
performed in duplicates and repeated three times. The amount of
each type of PCR product was normalised against b-actin and the
ratio between FL and AS was calculated for each tissue or cell line.
RESULTS
Identification and structure of a human splice variant of
CA IX
Alternative splicing of CA9 mRNA was first recognised in our RT–
PCR study of the mouse gastrointestinal tissues using the primers
for the amplification of exons 6–11. The mouse splicing variant
does not contain the exons 7 and 8 (GeneBank no. EF12497) and
codes for the CA IX protein with deleted amino acids 335–379,
which lacks the C-terminal part of the catalytic (CA) domain
(Supplementary Figure 1). The mouse AS protein expressed in the
transfected NIH 3T3 and MDCK cells produced a single 48K band
in immunoblotting and exhibited intracellular localisation in
immunofluorescence (Supplementary Figure 2).
This finding motivated us to search for the AS CA9 mRNA in
human tissues and cell lines. We designed a set of primers that
covered the entire human CA9 mRNA (Figure 1A). These were
employed in RT–PCR on cDNA templates reverse-transcribed
from mRNAs isolated from the human stomach and small
intestine. Using the primers designed against exons 1 and 6 we
hCA IX
h1S h6S h7S
h6A h8A h11A
h10/7A
12 3 4 5 6 7 8 9 1 0 1 1
AS-hCAIX
hCA IX
AS-hCAIX
hCA IX
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AS-hCAIX
hCA IX
AS-hCAIX
hCA IX
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CA9 FL+AS
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Intestine
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D
E
C
FL hCA IX
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TMIC CA PG
Figure 1 Identification and predicted structure of the human splicing
variant of CA IX. (A) Schematic illustration of the genomic structure of the
human CA9 gene (GenBank no. Z54349). Positions of primers are indicated
by arrows. Exons excluded by alternative splicing are in dark grey colour.
(B) RT–PCR analysis of CA9 in the human stomach, small intestine, and
colon using h1S-h6A primers that do not discriminate between the splicing
variants. (C) Amplification of both FL and AS transcripts in the human
tissues using h6S-h11A primers. (D) Comparison of amino acid sequences
deduced from the human FL and AS CA9 cDNAs. Signal peptide (SP) is
written in italic, proteoglycan-like domain (PG) is in bold, carbonic
anhydrase domain (CA) is on a grey background, and the transmembrane
region (TM) is written by white letters on a black background. Dashed lines
represent amino acid residues deleted in AS. Histidines that bind a catalytic
zinc and cysteines involved in formation of S-S bonds are placed on a dark
background (E) Predicted structure of the human FL and AS CA IX
proteins.
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sdetected only a predicted PCR product (Figure 1B). However, the
primers to exons 6 and 11 generated two PCR amplicons – a more
abundant longer product and a much less abundant shorter
product (Figure 1C). The intensity of the FL-related band was 19.8
times higher than that of the AS band in the stomach and 2.6 times
in the small intestine. Sequence analysis of the shorter product
confirmed that it corresponds to a human AS variant of CA9
mRNA. The splicing led to a deletion of exons 8 and 9 (GenBank
no. EF122496).
To facilitate a separate detection of the FL and AS variants of
CA9 mRNA, we utilised primers that allowed for their individual
amplification. The design was based on placing one FL-specific
primer (h8A) inside the deleted region and one AS-specific primer
(h10/7A) on the alternative splicing-generated junction. Each of
these primers was used in combination with h7S primer common
for both transcripts (Figure 1A). The resulting fragments were of
154bp (FL) and 140bp (AS) in length, respectively. To quantify the
amount of FL and AS transcripts and evaluate their relationship,
we performed real-time PCR using these primer combinations.
Results of three times repeated analyses revealed that the ratio of
FL to AS was 19.6±1.2 for the stomach (which is known to express
a very high level of FL), 17.3±1.1 for the small intestine, and
5.4±0.1 for the colon (which is known to express lower level of FL
than the stomach).
Computer-predicted human AS CA IX protein is lacking the
amino acids 356–412 and its deduced molecular weight is about
43K compared to a predicted size of 49K for the full-length
(FL) CA IX. The deletion eliminated 35 amino acids from the
C-terminal part of the catalytic CA domain and 21 amino acids
localised between the CA domain and the transmembrane region,
which include Cys
409 that appears to participate in the formation
of intermolecular S–S bonds (Figure 1D). Owing to a frameshift-
generated stop codon at position 1119bp in AS mRNA (in FL CA9
mRNA, the stop codon is at position 1142bp), the AS protein is
truncated and contains neither the transmembrane nor the
intracytoplasmic domains (Figure 1E).
Expression of human AS CA IX in tumour cell lines and
tissues
The primers suitable for individual amplification of AS and FL
were also used for the analysis of tumour cell lines and tissues.
First, we analysed the presence of the AS variant in the human
cancer cell lines exposed to hypoxia (2%) and normoxia (21%).
The AS variant was detected in all examined cell lines and
displayed similar levels under both normoxia and hypoxia
(Figure 2A). This was in contrast to FL CA9 mRNA, which was
clearly hypoxia-inducible and showed considerably increased
levels, namely in Caski, SiHa, and ACHN cells, whereas CAKI-1
cells expressed only a very low level of FL CA9 (Figure 2A). No FL
CA9-specific signal was observed in C33a cells that lack the CA9
gene (Lieskovska et al, 1999). Quantitative real-time PCR
confirmed these data by showing considerable increase of FL to
AS ratio under hypoxic conditions when compared to normoxia
(5-fold in SiHa cells, 27-fold in Caski cells, and 8-fold in ACHN
cells).
Previous studies have shown a density-induced expression of
the FL CA IX that was associated with pericellular hypoxia (Kaluz
et al, 2002). To see whether the expression of the AS variant is
density-dependent, we used HeLa and SiHa cells cultivated in
sparse culture (plated at 10000cellspercm
2) and dense culture
(80000cellspercm
2), respectively, for 24h. The dense cells clearly
showed normoxic expression of the FL CA9 mRNA, although its
level was lower than in the hypoxic cells. No remarkable
differences were observed between the cells cultivated in sparse
and dense monolayer with regard to level of the AS variant
(Figure 2B).
Finally, we analysed the AS expression in normal vs malignant
human tissues, including the stomach, colon, rectum, and liver.
Reverse transcriptase PCR revealed the presence of the AS variant
in all examined tissues (Figure 2C). In accord with the previous
studies, FL transcript was found only in the normal stomach and in
tumours derived from the colon and rectum (Saarnio et al, 1998;
Kivela et al, 2005).
Localisation and basic characteristics of the human AS
variant of CA IX
To perform a basic characterisation of the AS variant of CA IX, we
generated stable transfectants with ectopic expression of the
human AS protein. The human AS cDNA was transfected into CA
IX-negative MDCK cells in addition to human HeLa cervical
carcinoma cells that naturally express FL CA IX in response to
density and hypoxia. In accord with the computer analysis that
predicted splicing- and frameshift-mediated removal of TM and IC
regions, the AS CA IX protein was not confined to the plasma
membrane, but showed intracellular localisation in both, MDCK
cells and in normoxic HeLa cells (Figure 3A). This was clearly in
contrast with the cell surface localisation of the FL CA IX in the
MW ACHN CAKI-1 Caski SiHa
NHNHNHNH
H N H N H
Colon 1
MW
NTNTNTNTNTNT
Rectum 1 Colon 2 Liver Stomach
AGS
Rectum 2
N
Dense Dense
HeLa SiHa
Sparse Sparse
H N
C33a
FL-CA9
AS-CA9
-Actin
FL-CA9
FL-CA9
AS-CA9
AS-CA9
-Actin
-Actin
A
B
C
Figure 2 Expression of the AS CA IX variant in human tumour cell lines
and in human tissues. RT–PCR analysis of human AS CA9 using the primers
designed for individual amplification of the splicing variants, namely h7S-h8A
for FL and h7S-h10/7A for AS (see Figure 3). b-actin was used as a
standard. SmartLadder was included in the right side of the gels. The
cDNAs were isolated (A) from the cells exposed to normoxia (N) and
hypoxia (H) for 48h, (B) from the cells incubated at low and high density
for 72h, and (C) from normal and tumour human tissues. The results
indicate that the AS expression is steady and does not depend on hypoxia,
density, and tumour phenotype.
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stransfected MDCK cells and in the mock-transfected HeLa cells
exposed to hypoxia (2% O2).
The transfected HeLa-AS cells exhibited in immunoblotting two
bands of approximately 43–47K corresponding to the AS CA IX
and additional two bands of 54–58K corresponding to the
hypoxia- and density-induced FL CA IX (Figure 3B). Because of
the complete absence of the transmembrane and intracellular
domains from the AS protein we also assumed that at least a
portion of the AS CA IX molecules should be released into the
culture medium. To investigate this possibility, the cells were
cultivated under normoxia and hypoxia in the serum-free medium.
After 24h of incubation, one-fourth of the culture medium was
concentrated and analysed by SDS–PAGE. Immunoblotting
showed the presence of AS CA IX in the culture medium under
both, normoxia and hypoxia (Figure 3C). Taken together, these
data indicated that the AS is present in the intracellular as well as
extracellular space, in contrast to FL CA IX, which is mostly
confined to plasma membrane. Moreover, under non-reducing
conditions, the FL protein formed oligomers of about 153K,
whereas the AS CA IX variant was unable to do so and was also
unable to enter into oligomers built by FL CA IX protein
(Supplementary Figure 3, for details see Materials and Methods).
Functional properties of the human AS CA IX
Expression of the FL CA IX in tumour cells is induced by hypoxia.
Hypoxia also activates the catalytic performance of CA IX,
which results in enhanced acidification of extracellular pH
(Svastova et al, 2004). This acidification capacity can be abolished
by the overexpression of a dominant-negative mutant lacking
the catalytic CA domain of CA IX (Svastova et al, 2004). Since
the AS protein contains only incomplete CA domain, it was
particularly important to analyse whether it is catalytically active
and whether it is capable of disturbing acidification mediated by
the FL CA IX protein.
Measurement of an enzyme activity was accomplished by
stopped flow spectrometry using the recombinant bacterial GST-
AS fusion protein containing the truncated CA domain compared
to a GST-fused extracellular portion of the FL CA IX containing the
complete CA domain (GST-PGCA). The results revealed that the
catalytic activity of the wild-type CA IX, Kcat(WT)¼3.8 10
5s
 1,
was reduced to half in the splicing variant, Kcat(AS)¼1.9 10
5s
 1.
In addition, GST-AS protein showed considerably lower affinity for
acetazolamine, a sulphonamide inhibitor of carbonic anhydrases:
Ki WT¼14nM vs Ki AS¼110nM. These data suggest that splicing
has compromised both, the enzyme activity of CA IX and its
affinity to inhibitors.
MDCK
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Figure 3 Localisation of the human AS CA IX. CA IX-negative MDCK
cells and HeLa cells with natural hypoxia-induced expression of FL CA IX
were permanently transfected with AS CA9 cDNA in pSG5C plasmid. (A)
Immunofluorescence analysis of the AS-transfected (AS), FL-transfected
(FL), and control cells (mock) was performed using M75 MAb recognising
both AS and FL proteins. (B) Immunoblotting analysis of the protein
extracts from HeLa-AS and control HeLa cells plated in sparse (S), medium
(M), and dense (D) cultures, allowed to adhere for 24h and then incubated
for 24h in normoxia and hypoxia, respectively. Asterisk on the CA IX blot
indicates the position of 50KMw marker, a-tubulin was used as a loading
control. (C) The AS CA IX variant was also detected with M75 MAb in
culture medium of AS-transfected cells.
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Figure 4 Effect of overexpressed AS variant on acidification, inhibitor
binding, and spheroid formation. (A) The AS-transfected HeLa cells and
related mock-transfected controls were incubated for 48h in normoxia and
hypoxia, respectively, and extracellular pH was measured in culture
medium immediately at the end of experiment. Data are expressed as
differences between the pH values (DpH) measured in normoxic vs
hypoxic cells and include standard deviations. Results show that expression
of AS reduces the acidification mediated by FL CA IX protein under
hypoxia. (B) MDCK-CA IX transfected cells that constitutively express
human FL CA IX protein were treated for 48h by a fluorescent CA
inhibitor (FITC-CAI) in the absence (control) or in the presence of the
secreted AS variant added with the conditioned medium from MDCK-AS
transfectants. Conditioned medium was mixed with a fresh cultivation
medium. FITC-CAI bound only to hypoxic cells and was considerably
reduced in the presence of the AS protein. (C) The same experiment was
performed repeatedly with either one-half (1/2 AS) or one-third (1/3 AS)
of conditioned medium from MDCK-AS cells. Binding of FITC-CAI and
corresponding fluorescence was evaluated from acquired images using
Scion Image software. Data were expressed as a percentage of positive
control represented by hypoxic MDCK-CA IX cells incubated with FITC-
CAI in the absence of AS. The results confirmed that AS reduces the
binding of FITC-CAI to CA IX. (D) Microscopic images of spheroids grown
from control mock-transfected HeLa cells and from AS-transfected HeLa
cells, respectively. Control HeLa cells express hypoxia-induced, functional
FL CA IX protein, and produce spheroids that form compact cores. HeLa-
AS cells, which contain both hypoxia-induced FL CA IX and constitutively
expressed AS, contain loose cores possibly due to AS-compromised
function of FL leading to decreased survival of hypoxic core cells.
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capacity of the FL CA IX to acidify extracellular pH under hypoxic
conditions. For that purpose we analysed the transfected HeLa-AS
cells and the mock-transfected controls incubated for 48h in 2%
O2 (hypoxia) and 21% O2 (normoxia). Hypoxic incubation led
to expected extracellular acidification in the control and in AS-
transfected HeLa cells when compared to their normoxic counter-
parts (Figure 4A). However, the medium was approximately 0.2pH
unit less acidified in the AS-overexpressing cells, suggesting that
the AS disturbed the activity of the wild-type CA IX protein.
Since the catalytic site of CA IX is exposed to extracellular space,
we tested a possible role of the extracellular fraction of AS. As
described earlier, the activity of CA IX can be indirectly
demonstrated using the fluorescein-labelled CA inhibitor (FITC-
CAI) that binds only to hypoxia-activated CA IX whose catalytic
site is accessible by the inhibitor (Svastova et al, 2004). Therefore,
we used an established model of CA IX-transfected MDCK cells
that show CA IX-mediated extracellular acidification when treated
by hypoxia and accumulate FITC-CAI in hypoxia but not in
normoxia. Here we analysed the accumulation of FITC-CAI in
MDCK-CA IX cells in the presence and absence of the culture
medium from the AS-secreting MDCK-AS transfectants. As shown
on Figure 4B, incubation of MDCK-CA IX cells in the fresh
medium mixed with the AS-containing conditioned medium
resulted in visibly reduced accumulation of FITC-CA IX supporting
the idea that the extracellular AS diminished the binding of the
inhibitor. This experiment has been repeated with one-half and
one-third of the AS-containing conditioned medium. The acquired
images were analysed to determine the differences in the intensity
of fluorescence. The results clearly proved that the extracellular
fraction of AS reduced FITC-CAI accumulation approximately to
one half (Figure 4C).
To see whether the effect of the AS variant on the functioning of
the FL CA IX could have biological consequences, we analysed the
growth parameters of the HeLa-AS transfectants compared to the
mock-transfected controls. No significant differences were ob-
served between these two cell types upon their short-term (72h)
growth in the adherent culture independently of normoxic or
hypoxic conditions (data not shown). Therefore, we also produced
HeLa cell spheroids grown for 14 days and compared the mass and
shape of the spheroids generated from the HeLa-AS cells and the
control HeLa cells, respectively. The HeLa-AS spheroids were less
compact and lacked the central region, which usually contains the
cells that suffer from low oxygen and acidic pH (Figure 4D). The
appearance of these HeLa-AS spheroids suggested that the effect of
AS, which leads to reduced capacity of the FL CA IX to modulate
pH could influence the capability of cells to survive these
microenvironmental stresses.
Altogether, our results showed that the AS CA IX is differently
regulated, abnormally localised, and functionally diminished when
compared to FL CA IX.
DISCUSSION
Alternative splicing is an important molecular mechanism that
significantly contributes to structural and functional diversifica-
tion of proteins. It frequently results from differential exon
inclusion and leads to altered domain composition, subcellular
localisation, interaction potential, signalling capacity, and other
changes at the protein level. Data obtained by recent genomic
technologies indicate that over 60% of human genes are
alternatively spliced. It is also becoming more and more evident
that imbalances in the expression of alternative splicing variants
can significantly affect cell phenotype and play a role in various
pathologies (Matlin et al, 2005).
Deregulation of alternative splicing is a well-recognised
phenomenon particularly in cancer (Venables, 2006). There are
numerous examples of alternatively spliced genes whose products
are causally involved in tumour progression, such as CD44, HIF-a,
VEGF, osteopontin, and many others (Gothie et al, 2000; Robinson
and Stringer, 2001; Wong et al, 2003; He et al, 2006). In some cases,
the splice form that is rare in normal tissues can become common
in tumours, while the alternative splice form present in normal
tissues can remain constant (Roy et al, 2005).
The alternative splicing variant of the human CA IX identified in
this study can be classified to this category, although it is difficult
to make a clear-cut conclusion, since the expression pattern of the
full-length CA IX is quite particular. The FL CA IX is abundant in
very few normal tissues including the stomach and small intestine,
which at the same time express a low level of the alternative-
splicing variant. In gastric carcinomas, the expression of the FL CA
IX decreases, but the level of AS is similar as in the normal
stomach. In contrast, the expression of the full-length CA IX is
absent or very low in the normal colon and rectum (and also in
additional normal tissues not analysed in this study) and
significantly increases in corresponding tumours (Saarnio et al,
1998). However, the AS variant shows a steady expression level in
both normal tissues and colorectal carcinomas. These data
strongly suggest that its expression is not linked to tumour
phenotype. Moreover, in contrast to the FL CA IX whose levels are
induced in the cells growing in crowded culture and exposed to
low oxygen, the AS variant is not principally dependent on hypoxia
and cell density.
Relatively low, but steady expression of AS is of considerable
importance for clinical studies using CA9 transcription as a marker
of hypoxic tumours for potential prognostic or predictive
purposes. Because of the presence of the AS CA9 transcript in
the normal and/or non-hypoxic tissues, primers or probes
designed for detection of the regions that are not affected by
splicing cannot differentiate between the two forms of CA9 mRNA
and thus might give false-positive results, which could influence
the real clinical value of the hypoxia-induced FL CA9.
It is noteworthy that 50 RACE analysis of the AS mRNA
compared to the FL transcript has generated products of identical
length supporting the conclusion that both variants are produced
from the same promoter (data not shown). This fact might suggest
a differential cooperation of the transcriptional apparatus with the
components of the splicing machinery in the processing of the CA9
transcript depending on the physiological circumstances. Indeed,
there are several examples of the splicing events regulated by
hypoxia such as those related to hTERT, TrkA, and XBP1
(Romero-Ramirez et al, 2004; Taconelli et al, 2004; Anderson
et al, 2006). In the case of hTERT, it has been demonstrated that
the transcriptional complex containing RNA polymerase II, TFIIB,
HIF, and coactivators recruits at the promoter under hypoxia and
remains associated with the gene as long as transcription proceeds.
This induces a switch in the splice pattern in favour of an active
form of the enzyme (Anderson et al, 2006). A similar mechanism
might operate during the transcription of the CA9 gene. In
addition, recent studies show that splicing can respond to changes
in the extracellular microenvironment (Pleiss et al, 2007) or to
signal transduction through post-translational modifications of
spliceosome components (reviewed in Shin and Manley, 2004). For
example, activation of the Ras pathway induces inclusion of the
metastasis-associated exon v5 in CD44 transcript via phosphoryla-
tion of the RNA-binding protein Sam68 and via splicing of the
coactivator SRm160 (Matter et al, 2002; Cheng and Sharp, 2006).
So, it is quite possible that FL splicing is induced in the presence of
hypoxia by HIF pathway-stimulated modification of splicing
factors.
The AS variant of the human CA9 mRNA results from the
deletion of exons 8 plus 9 and is translated to truncated protein,
which does not contain the transmembrane region, intracellular
tail, and C-terminal part of the catalytic domain. Removal of the
TM and IC regions is apparently responsible for the altered
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intracellular space and is also released to the extracellular medium.
This is in contrast with the FL CA IX protein, which is an integral
plasma membrane protein. Such inappropriate localisation linked
with a partial deletion of the catalytic domain can be expected to
compromise the protein functionality. Indeed, GST-AS shows only
one half of the enzyme activity of the corresponding GST-PGþCA
protein containing the complete catalytic domain. However, it is
very difficult to translate this finding directly into local cellular
context, where CA IX interacts with bicarbonate transporters and
contributes to pH regulation across the plasma membrane under
hypoxic conditions (Svastova et al, 2004; Morgan et al, 2007;
Swietach et al, 2007). First, activity measurements were performed
with the proteins produced in bacteria in a setting free of any
subcellular structures, protein–protein interactions, ion fluxes,
and microenvironmental influences, which certainly play a role in
modulating the catalytic performance of CA IX. Second, the
catalytic activities of different carbonic anhydrase isoenzymes vary
roughly within two orders of magnitude, with the highly active
isoforms showing from 20 to only 3 times higher activity than the
isoenzymes that are considered moderate (Pastorekova et al,
2004). So it is not possible to preclude whether the half-reduced
activity would be sufficient for the physiological function of CA IX.
Anyhow, this question is probably not critical, since the AS variant
is not properly localised at the plasma membrane and is unable to
form oligomers, which are very important constraints for the CA
IX protein functioning.
However, reduced extracellular acidification observed in the
culture of hypoxic HeLa-AS cells that constitutively overexpress
the AS form of CA IX clearly indicates that it interferes with the
function of endogenous, hypoxia-induced FL protein. Although the
mechanism is not clear at present, based on the decreased
accumulation of CA inhibitor in the hypoxic MDCK-CA IX cells
treated with the secreted AS variant, we can propose that AS might
compete with the FL CA IX for an interaction with the cell surface
components of the bicarbonate transport metabolon (since this
interaction appears to include the extracellular portion of CA IX as
demonstrated by Morgan et al, 2007). Moreover, overexpression of
AS considerably affects the capacity of HeLa cells to form compact
spheroids, which are often used as a 3D model that mimics tumour
mass with corresponding intratumoral microenvironment. Many
studies well document gradients of oxygen partial pressure, pH,
nutrients, and metabolites across the spheroids whose core regions
show a clear analogy with the hypoxic areas of solid tumours that
are characterised by a more acidic microenvironment (Alvarez-
Pe ´rez et al, 2005). It has been shown elsewhere that the plasma
membrane staining of the FL CA IX is significantly increased in the
innermost cells of multicellular spheroids generated from SiHa and
HeLa cervical carcinoma cells (Olive et al, 2001; Chrastina et al,
2003). These data indicate that FL CA IX is present exactly in the
areas where the cells need increased protection and/or adaptation
to harmful effects of the hypoxic stress and acidic microenviron-
ment to survive. The FL CA IX acts here via bicarbonate-mediated
buffering of intracellular pH (Swietach et al, 2007). The AS variant
that partially perturbs this pH regulation, obviously does not
permit the adaptation to acidic intra-spheroid pH, leading to
elimination of the most stressed central cells from the core of
spheroids. This idea is consistent with the findings that the
catalytic activity of CA IX is regulated by hypoxia and suggests
that the capacity of CA IX to modulate pH is vital for the survival
of hypoxic tumour cells. The latter suggestion has been indirectly
supported also by RNAi experiments by Robertson et al
(2004). However, it is also possible that the AS protein released
to the culture medium can modulate spheroid formation via
binding to the transport unrelated receptor and stimulate or block
signal transduction in autocrine or paracrine fashion. The
literature contains several examples of splicing-truncated proteins
functioning in this manner (Aasheim et al, 2000; Huang et al,
2006).
Although the naturally produced AS variant is expressed at a low
level, there are physiological situations and cell types that only
weakly induce FL CA IX. For example tumour cells localised at
shorter distances from functional blood-supplying vessels are
exposed to mild hypoxia and may express comparable levels of FL
and AS thus allowing for dominant-negative down modulation of
CA IX activity. Such weakly hypoxic cells are presumably not
exposed to severe acidosis and therefore may not benefit from full
performance of this pH control mechanism. A similar explanation
can be applied also to normal tissues suffering from mild
ischaemia. This idea finds support in the recent as well as previous
data showing that some tumour cell lines, dense normoxic
cells (affected by weak pericellular hypoxia) and some early stage
less-hypoxic tumours express just low levels of FL CA IX. In
conclusion, we propose that the AS variant functions as a
modulator of the FL CA IX under circumstances when both
proteins are coexpressed.
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